Stock recommended as a "buy" with "target price of 60 based on core laboratory business and contraction of the CRO industry which should allow CVD to survive and thrive as the CRO industry contracts. The ability to offer lab and clinical services as a bundled package should help Covance retain market share. Company has too much management, and needs to cut costs. Management should start a share dividend payment to radically move the stock price up."